Voyager Therapeutics (VYGR) announced positive topline data from the Company’s single ascending dose, SAD, trial of VY7523, an investigational ...

Voyager Therapeutics announced positive results from the single ascending dose (SAD) trial of its investigational anti-tau antibody, VY7523, which demonstrates safety, tolerability, and dose ...

(RTTNews) - Voyager Therapeutics, Inc. (VYGR) Monday announced positive topline data from its single ascending dose (SAD) study of VY7523 developed for the treatment of Alzheimers disease (AD).

VY7523 is designed as an intravenous anti-tau antibody to selectively inhibit the spread of pathological tau, a protein linked to disease progression and cognitive decline in Alzheimer's.

Voyager Therapeutics (VYGR) said on Monday that the company provided positive topline data from its early stage trial of VY7523, an antibody to selectively inhibit the spread of pathological tau in ...

The company recently completed enrollment for its VY7523 trial for Alzheimer’s disease with data expected in 2025. The company’s strong financial position and promising Alzheimer’s program ...

The company recently completed enrollment for its VY7523 trial for Alzheimer’s disease with data expected in 2025. The company’s strong financial position and promising Alzheimer’s program ...

The firm specifically highlighted the potential of Voyager’s tau-targeting therapies, VY7523 and VY1706, and its TRACER platform. Citi also initiated a Buy rating for Voyager, with a price target of ...

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotech firm focusing on neurogenetic medicines, has announced encouraging preliminary results from a clinical trial of its Alzheimer’s ...